Genovate Biotechnology Co., Ltd. (TPEX:4130)
Taiwan
· Delayed Price · Currency is TWD 34.60
-0.35 (-1.00%)
At close: Mar 6, 2026
Genovate Biotechnology Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 492.41 | 510.86 | 528.51 | 438.76 | 434.25 | Upgrade
|
| Revenue Growth (YoY) | -3.61% | -3.34% | 20.46% | 1.04% | -8.14% | Upgrade
|
| Cost of Revenue | 315.38 | 318.21 | 317.6 | 283.89 | 284.5 | Upgrade
|
| Gross Profit | 177.02 | 192.65 | 210.92 | 154.87 | 149.75 | Upgrade
|
| Selling, General & Admin | 112.2 | 109.74 | 110.31 | 106.89 | 95.49 | Upgrade
|
| Research & Development | 57.91 | 59.49 | 73.61 | 61.88 | 55.43 | Upgrade
|
| Operating Expenses | 170.11 | 169.22 | 183.91 | 168.76 | 150.92 | Upgrade
|
| Operating Income | 6.92 | 23.43 | 27.01 | -13.89 | -1.17 | Upgrade
|
| Interest Expense | -0.68 | -0.52 | -0.27 | -0.28 | -0.25 | Upgrade
|
| Interest & Investment Income | 6.29 | 6.5 | 5.02 | 2.67 | 1.61 | Upgrade
|
| Earnings From Equity Investments | -2.26 | -0.96 | -3.88 | 0.29 | 0.14 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.24 | 0.43 | 0.21 | 0.44 | -0.19 | Upgrade
|
| Other Non Operating Income (Expenses) | 2.46 | 1.71 | 2.29 | 1.65 | 3.44 | Upgrade
|
| EBT Excluding Unusual Items | 12.97 | 30.59 | 30.39 | -9.12 | 3.57 | Upgrade
|
| Gain (Loss) on Sale of Investments | 0.49 | 0.47 | 0.45 | 0.07 | - | Upgrade
|
| Other Unusual Items | - | - | -0.01 | 0.05 | - | Upgrade
|
| Pretax Income | 13.45 | 31.06 | 30.83 | -9 | 3.57 | Upgrade
|
| Income Tax Expense | 1.77 | 5.36 | 1.49 | 3.32 | 3.2 | Upgrade
|
| Net Income | 11.68 | 25.7 | 29.33 | -12.32 | 0.37 | Upgrade
|
| Net Income to Common | 11.68 | 25.7 | 29.33 | -12.32 | 0.37 | Upgrade
|
| Net Income Growth | -54.54% | -12.39% | - | - | -99.04% | Upgrade
|
| Shares Outstanding (Basic) | 114 | 115 | 115 | 113 | 113 | Upgrade
|
| Shares Outstanding (Diluted) | 114 | 115 | 115 | 113 | 113 | Upgrade
|
| Shares Change (YoY) | -0.81% | -0.24% | 1.49% | -0.03% | -0.14% | Upgrade
|
| EPS (Basic) | 0.10 | 0.22 | 0.26 | -0.11 | 0.00 | Upgrade
|
| EPS (Diluted) | 0.10 | 0.22 | 0.25 | -0.11 | 0.00 | Upgrade
|
| EPS Growth | -54.55% | -13.69% | - | - | -99.15% | Upgrade
|
| Free Cash Flow | -11.94 | 24.34 | 56.81 | -22.04 | -35.22 | Upgrade
|
| Free Cash Flow Per Share | -0.10 | 0.21 | 0.49 | -0.19 | -0.31 | Upgrade
|
| Dividend Per Share | - | 0.100 | 0.143 | 0.167 | 0.333 | Upgrade
|
| Dividend Growth | - | -29.97% | -14.29% | -49.98% | -12.94% | Upgrade
|
| Gross Margin | 35.95% | 37.71% | 39.91% | 35.30% | 34.48% | Upgrade
|
| Operating Margin | 1.40% | 4.59% | 5.11% | -3.17% | -0.27% | Upgrade
|
| Profit Margin | 2.37% | 5.03% | 5.55% | -2.81% | 0.09% | Upgrade
|
| Free Cash Flow Margin | -2.42% | 4.76% | 10.75% | -5.02% | -8.11% | Upgrade
|
| EBITDA | 42.03 | 58.01 | 60.9 | 19.94 | 32.33 | Upgrade
|
| EBITDA Margin | 8.54% | 11.36% | 11.52% | 4.54% | 7.45% | Upgrade
|
| D&A For EBITDA | 35.12 | 34.58 | 33.9 | 33.83 | 33.5 | Upgrade
|
| EBIT | 6.92 | 23.43 | 27.01 | -13.89 | -1.17 | Upgrade
|
| EBIT Margin | 1.40% | 4.59% | 5.11% | -3.17% | -0.27% | Upgrade
|
| Effective Tax Rate | 13.17% | 17.26% | 4.84% | - | 89.57% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.